论文部分内容阅读
一项随机试验结果显示,2型糖尿病患者可采用血管紧张素受体拮抗剂(ARB)来延缓微量白蛋白尿的发生,但同时心血管死亡风险也随之增加。根据Hermann Haller医师(汉诺威医学院,
In a randomized trial, angiotensin receptor blockers (ARBs) were used to delay the development of microalbuminuria in patients with type 2 diabetes but at the same time the risk of cardiovascular death was increased. According to Hermann Haller (Hannover Medical School,